AgeCurve is a biotechnology company that uses evolutionary cell lineage trees to unlock the predictive power somatic mutations.
AgeCurve has raised $313K in total funding. The most recent round was Seed. The last funding was announced in February 2024.
AgeCurve's investors include Longevitytech.fund.
AgeCurve is headquartered in Cambridge, United Kingdom.
AgeCurve is a biotechnology company that uses evolutionary cell lineage trees to unlock the predictive power somatic mutations.
AgeCurve is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"AgeCurve — Funding & Investors." VCBacked, February 5, 2024, https://www.vcbacked.co/company/agecurve. Accessed October 6, 2026.
VCBacked. (2024). AgeCurve — Funding & Investors. Retrieved October 6, 2026, from https://www.vcbacked.co/company/agecurve
{{cite web |title=AgeCurve — Funding & Investors |url=https://www.vcbacked.co/company/agecurve |website=VCBacked |access-date=October 6, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated